Puma Biotechnology Falls As It Posts Mediocre Breast Cancer Results
May 14, 2015 at 14:54 PM EDT
Shares of Puma Biotechnology are trading down 19% after the company reported mediocre efficacy and safety problems with its drug
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.